Literature DB >> 35015113

Comments on the paper "Clinical characteristics and treatment of pars planitis: an adalimumab experience" by Ozdemir et al.

Francois Pepin1, Rachael L Niederer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015113     DOI： 10.1007/s00417-021-05527-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis.

Authors:  Manabu Mochizuki; Justine R Smith; Hiroshi Takase; Toshikatsu Kaburaki; Nisha R Acharya; Narsing A Rao
Journal:  Br J Ophthalmol       Date:  2019-02-23       Impact factor: 4.638

2.  Utility of Screening Investigations for Systemic Sarcoidosis in Undifferentiated Uveitis.

Authors:  Rachael L Niederer; Joanne L Sims
Journal:  Am J Ophthalmol       Date:  2019-04-19       Impact factor: 5.258

Review 3.  Demyelination and other neurological adverse events after anti-TNF therapy.

Authors:  Evripidis Kaltsonoudis; Paraskevi V Voulgari; Spyridon Konitsiotis; Alexandros A Drosos
Journal:  Autoimmun Rev       Date:  2013-09-12       Impact factor: 9.754

Review 4.  Insights into multiple sclerosis-associated uveitis: a scoping review.

Authors:  Pauline Casselman; Cathérine Cassiman; Ingele Casteels; Pieter-Paul Schauwvlieghe
Journal:  Acta Ophthalmol       Date:  2020-12-16       Impact factor: 3.761

5.  Clinical characteristics and treatment of pars planitis: an adalimumab experience.

Authors:  Huseyin Baran Ozdemir; Pinar Cakar Ozdal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-27       Impact factor: 3.117
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.